TScan is a clinical-stage biopharmaceutical company dedicated to changing lives by discovering new cancer targets and developing safe and effective T cell therapies for patients.
TScan’s therapeutic approach is based on the central premise that we can learn from patients who are winning their fight against cancer in order to treat those who are not.
Scientific Co-founder of TScan
Dana-Farber Cancer Institute
Houston Methodist Hospital
Professor Emeritus, Medicine, Harvard Medical School
Assistant Professor of Pathology, Johns Hopkins Medicine
Assistant Member at Fred Hutch
